"The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa&rsqu"...
Kayexalate (sodium polystyrene) may cause some degree of gastric irritation. Anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. Also, hypokalemia, hypocalcemia, hypomagnesemia and significant sodium retention, and their related clinical manifestations, may occur (see WARNINGS). Occasionally diarrhea develops. Large doses in elderly individuals may cause fecal impaction (see PRECAUTIONS). Rare instances of intestinal necrosis have been reported. Intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with Kayexalate (sodium polystyrene) , has been reported.
The following events have been reported from worldwide post marketing experience:
- Fecal impaction following rectal administration, particularly in children;
- Gastrointestinal concretions (bezoars) following oral administration;
- Ischemic colitis, gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation; and,
- Rare cases of acute bronchitis and/or broncho-pneumonia associated with inhalation of particles of polystyrene sulfonate.
Read the Kayexalate (sodium polystyrene) Side Effects Center for a complete guide to possible side effects
The simultaneous oral administration of Kayexalate (sodium polystyrene) with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability.
Non-absorbable cation-donating antacids and laxatives
Systemic alkalosis has been repotted after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with Kayexalate (sodium polystyrene) . One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given Kayexalate (sodium polystyrene) with magnesium hydroxide as a laxative.
Intestinal obstruction due to concretions of aluminum hydroxide when used in combination with Kayexalate (sodium polystyrene) has been reported.
The toxic effects of digitalis on the heart, especially various ventricular arrhythmias and A-V nodal dissociation, are likely to be exaggerated by hypokalemia, even in the face of serum digoxin concentrations in the "normal range" (See WARNINGS).
Sorbitol: Concomitant use of Sorbitol with Kayexalate (sodium polystyrene) has been implicated in cases of intestinal necrosis, which may be fatal. Therefore, concomitant administration is not recommended (See WARNINGS).
Kayexalate (sodium polystyrene) may decrease absorption of lithium.
Kayexalate (sodium polystyrene) may decrease absorption of thyroxine.
Read the Kayexalate Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 2/28/2011
Additional Kayexalate Information
Kayexalate - User Reviews
Kayexalate User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.